• Sunday, Aug 01, 2021
  • Last Update : 09:17 am

Beximco Pharma reports 41% profit in 9 months of FY21

  • Published at 08:09 pm April 29th, 2021
Beximco Pharma’s

They made Tk370.60, crore profit in the first nine months of the financial year

Beximco Pharma saw its net profit soar more than 41% in the first nine months of FY21 (July’20-March’21) to Tk370.60, crore as the local drugmaker continues to make the most of the challenges hurled by the Covid-19 pandemic.

Their profit in the third quarter of its 2020-21 financial year stood at Tk370.60 crore, a 41.28% increase from Tk262.31 crore for the same period of the last year.

The leading pharma company’s earnings per share (EPS) was Tk8.23 for Jul’20-Mar’21 against Tk5.84 for the same period last year.

In the last three months (Jan-Mar’21), the company's net profit stood at Tk147 crore as against Tk90.92 crore for the same period last year.

Its consolidated EPS stood at Tk3.28, against Tk2.02 for the same period last year.


Also Read: Numbers are in and Beximco is indeed on a dream run


The pharmaceutical giant is supplying the Bangladesh government with 30 million doses of the Oxford University-AstraZeneca coronavirus vaccine by Serum Institute of India (SII).

This takes its total sales in the first half (Jul’-Dec’20) of the financial year to Tk1,440 crore, up 15.2% from a year earlier.

The higher sales numbers are not at all unexpected.

Back in May last year, when the world was gripped by fear of the rogue virus that jumped out of Wuhan, China, the company grabbed headlines globally for being the first company to market remdesivir, the antiviral drug that showed promise then in treating COVID-19 patients.

The company exported the drug as well as other medications to treat Covid-19 to a host of countries. It has been supplying the medications at home, too.

Subsequently, its profit and sales are scaling new highs.

It is no surprise then that shares of Beximco Pharma have been on the rise since June after the Dhaka bourse resumed from the 66-day recess in line with the government’s countrywide general shutdown to slow the spread of coronavirus.


Also Read: Beximco Pharma to acquire Sanofi Bangladesh for at least £35.5m


Beximco Pharma declined to comment on the report.

Beximco Pharma’s stock price soared more than two-and-a-half times. On Thursday, they closed at Tk192, in contrast to Tk70.3 on June 1, when trading resumed at the bourse.

A recent study by LankaBangla Investment Ltd revealed that local players dominate Bangladesh's pharmaceutical market. The Square Pharmaceuticals holds 17.73% of market share, while Incepta holds 10.21%, Beximco 8.39%, Opsonin 5.54%, Renata 4.97%, Healthcare Pharma 4.57%, ACI 4.43%, Aristo pharma 4.38%, Eskayef 4.36%, and The Acme holds 3.91%.

262
Facebook 258
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail